

Epilepsy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/E3E6FB1485F6EN.html>

Date: March 2022

Pages: 681

Price: US\$ 2,500.00 (Single User License)

ID: E3E6FB1485F6EN

Abstracts

Epilepsy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Epilepsy - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Epilepsy (Central Nervous System) pipeline landscape.

Epilepsy is a neurological disorder characterized by the transmission of abnormal signals produced by a group of neurons in the brain which causes seizures. This leads to brief disruptions of the senses and short periods of unconsciousness or convulsions. Symptoms of epilepsy are repeated seizures, weakness, and anxiety, loss of consciousness and contraction, or jerking, of body muscles. Main causes of epilepsy include low oxygen during birth, head injuries that occur during birth or from accidents during youth or adulthood, brain tumors, genetic conditions that result in brain injury, such as tuberous sclerosis, infections such as meningitis or encephalitis, and stroke or any other type of damage to the brain.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Epilepsy - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under

development for Epilepsy (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Epilepsy (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Epilepsy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 2, 14, 28, 27, 4, 141, 41 and 6 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 2, 23 and 3 molecules, respectively.

Epilepsy (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Epilepsy (Central Nervous System).

The pipeline guide reviews pipeline therapeutics for Epilepsy (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Epilepsy (Central Nervous System) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Epilepsy (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Epilepsy (Central Nervous System)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Epilepsy (Central Nervous System).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Epilepsy

(Central Nervous System) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

- Introduction
- Global Markets Direct Report Coverage
- Epilepsy - Overview
- Epilepsy - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Epilepsy - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Epilepsy - Companies Involved in Therapeutics Development
- Epilepsy - Drug Profiles
- Epilepsy - Dormant Projects
- Epilepsy - Discontinued Products
- Epilepsy - Product Development Milestones
- Featured News & Press Releases
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Epilepsy, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Companies, 2022 (Contd..1)

Number of Products under Development by Companies, 2022 (Contd..2)

Number of Products under Development by Companies, 2022 (Contd..3)

Number of Products under Development by Companies, 2022 (Contd..4)

Number of Products under Development by Companies, 2022 (Contd..5)

Number of Products under Development by Companies, 2022 (Contd..6)

Number of Products under Development by Companies, 2022 (Contd..7)

Number of Products under Development by Companies, 2022 (Contd..8)

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Companies, 2022 (Contd..1)

Products under Development by Companies, 2022 (Contd..2)

Products under Development by Companies, 2022 (Contd..3)

Products under Development by Companies, 2022 (Contd..4)

Products under Development by Companies, 2022 (Contd..5)

Products under Development by Companies, 2022 (Contd..6)

Products under Development by Companies, 2022 (Contd..7)

Products under Development by Companies, 2022 (Contd..8)

Products under Development by Companies, 2022 (Contd..9)

Products under Development by Companies, 2022 (Contd..10)

Products under Development by Companies, 2022 (Contd..11)

Products under Development by Companies, 2022 (Contd..12)

Products under Development by Companies, 2022 (Contd..13)

Products under Development by Companies, 2022 (Contd..14)

Products under Development by Companies, 2022 (Contd..15)

Products under Development by Companies, 2022 (Contd..16)

Products under Development by Companies, 2022 (Contd..17)

Products under Development by Companies, 2022 (Contd..18)

Products under Development by Universities/Institutes, 2022

Products under Development by Universities/Institutes, 2022 (Contd..1)

Number of Products by Stage and Target, 2022

Number of Products by Stage and Target, 2022 (Contd..1)

Number of Products by Stage and Target, 2022 (Contd..2)

Number of Products by Stage and Target, 2022 (Contd..3)
Number of Products by Stage and Target, 2022 (Contd..4)
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)
Number of Products by Stage and Mechanism of Action, 2022 (Contd..2)
Number of Products by Stage and Mechanism of Action, 2022 (Contd..3)
Number of Products by Stage and Mechanism of Action, 2022 (Contd..4)
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Epilepsy - Pipeline by a:head Bio AG, 2022
Epilepsy - Pipeline by Aadi Bioscience Inc, 2022
Epilepsy - Pipeline by Accure Therapeutics SL, 2022
Epilepsy - Pipeline by Advanced Neural Dynamics Inc, 2022
Epilepsy - Pipeline by Advicenne SA, 2022
Epilepsy - Pipeline by Aequus Pharmaceuticals Inc, 2022
Epilepsy - Pipeline by AfaSci Inc, 2022
Epilepsy - Pipeline by Affectis Pharmaceuticals AG, 2022
Epilepsy - Pipeline by AgoneX Biopharmaceuticals Inc, 2022
Epilepsy - Pipeline by Altamira Therapeutics Ltd, 2022
Epilepsy - Pipeline by AMO Pharma Ltd, 2022
Epilepsy - Pipeline by Anavex Life Sciences Corp, 2022
Epilepsy - Pipeline by Aphios Corp, 2022
Epilepsy - Pipeline by Apteeus SAS, 2022
Epilepsy - Pipeline by Aquestive Therapeutics Inc, 2022
Epilepsy - Pipeline by Arovella Therapeutics Ltd, 2022
Epilepsy - Pipeline by Aucta Pharmaceuticals LLC, 2022
Epilepsy - Pipeline by Aurum Biosciences Ltd, 2022
Epilepsy - Pipeline by Avicanna Inc, 2022
Epilepsy - Pipeline by Azurity Pharmaceuticals Inc, 2022
Epilepsy - Pipeline by B&A Therapeutics, 2022
Epilepsy - Pipeline by Baergic Bio Inc, 2022
Epilepsy - Pipeline by BCWorld Pharm Co Ltd, 2022
Epilepsy - Pipeline by Bio-Pharm Solutions Co Ltd, 2022
Epilepsy - Pipeline by Bioasis Technologies Inc, 2022
Epilepsy - Pipeline by Bioinnotis, 2022
Epilepsy - Pipeline by Biom Therapeutics LLC, 2022
Epilepsy - Pipeline by Biorchestra Co Ltd, 2022
Epilepsy - Pipeline by Biovista Inc, 2022
Epilepsy - Pipeline by Bloom Science Inc, 2022

Epilepsy - Pipeline by Bright Minds Biosciences Inc, 2022
Epilepsy - Pipeline by Bristol-Myers Squibb Co, 2022
Epilepsy - Pipeline by CAMP4 Therapeutics Corp, 2022
Epilepsy - Pipeline by Cann Pharmaceutical Australia Ltd, 2022
Epilepsy - Pipeline by Cavion LLC, 2022
Epilepsy - Pipeline by Celavie Biosciences LLC, 2022
Epilepsy - Pipeline by Cellix Bio Pvt Ltd, 2022
Epilepsy - Pipeline by Cerebral Therapeutics Inc, 2022
Epilepsy - Pipeline by Cerecin Pte Ltd, 2022
Epilepsy - Pipeline by Cerevel Therapeutics Holdings Inc, 2022
Epilepsy - Pipeline by Coda Biotherapeutics Inc, 2022
Epilepsy - Pipeline by Corestem Inc, 2022
Epilepsy - Pipeline by Corlieve Therapeutics SAS, 2022
Epilepsy - Pipeline by Crossject SA, 2022
Epilepsy - Pipeline by CSL Ltd, 2022
Epilepsy - Pipeline by Cure Pharmaceutical Holding Corp, 2022
Epilepsy - Pipeline by CuroNZ Ltd, 2022
Epilepsy - Pipeline by CURx Pharmaceuticals Inc, 2022
Epilepsy - Pipeline by Cypralis Ltd, 2022
Epilepsy - Pipeline by Eisai Co Ltd, 2022
Epilepsy - Pipeline by Eliem Therapeutics Inc, 2022
Epilepsy - Pipeline by Encoded Therapeutics Inc, 2022
Epilepsy - Pipeline by Engrail Therapeutics Inc, 2022
Epilepsy - Pipeline by Epalex Corp, 2022
Epilepsy - Pipeline by EpyGenix Therapeutics Inc, 2022
Epilepsy - Pipeline by Equilibre Biopharmaceuticals Corp, 2022
Epilepsy - Pipeline by ES Therapeutics LLC, 2022
Epilepsy - Pipeline by Eton Pharmaceuticals Inc, 2022
Epilepsy - Pipeline by Ferring Pharmaceuticals Inc, 2022
Epilepsy - Pipeline by GABA Therapeutics Inc, 2022
Epilepsy - Pipeline by GAOMA Therapeutics, 2022
Epilepsy - Pipeline by Gene Therapy Research Institution Co Ltd, 2022
Epilepsy - Pipeline by GenEp Inc, 2022
Epilepsy - Pipeline by Genochem SAS, 2022
Epilepsy - Pipeline by Genus Lifesciences Inc, 2022
Epilepsy - Pipeline by Guangzhou Cellprotek Pharmaceutical Co Ltd, 2022
Epilepsy - Pipeline by H. Lundbeck AS, 2022
Epilepsy - Pipeline by Harbin Pharmaceutical Group Co Ltd, 2022
Epilepsy - Pipeline by Herophilus, 2022

Epilepsy - Pipeline by ImmunoChem Therapeutics LLC, 2022
Epilepsy - Pipeline by InteRNA Technologies BV, 2022
Epilepsy - Pipeline by Ionis Pharmaceuticals Inc, 2022
Epilepsy - Pipeline by Iproteos SL, 2022
Epilepsy - Pipeline by iQure Pharma Inc, 2022
Epilepsy - Pipeline by Jazz Pharmaceuticals Plc, 2022
Epilepsy - Pipeline by JC Pharma Inc, 2022
Epilepsy - Pipeline by Johnson & Johnson, 2022
Epilepsy - Pipeline by Ketogen Inc, 2022
Epilepsy - Pipeline by Klaria Pharma Holding AB, 2022
Epilepsy - Pipeline by Knopp Biosciences LLC, 2022
Epilepsy - Pipeline by LATITUDE Pharmaceuticals Inc, 2022
Epilepsy - Pipeline by Lead Discovery Center GmbH, 2022
Epilepsy - Pipeline by Lexaria Bioscience Corp, 2022
Epilepsy - Pipeline by LifeSplice Pharma LLC, 2022
Epilepsy - Pipeline by Lipocine Inc, 2022
Epilepsy - Pipeline by Longboard Pharmaceuticals Inc, 2022
Epilepsy - Pipeline by Luminus Biosciences Inc, 2022
Epilepsy - Pipeline by Marinus Pharmaceuticals Inc, 2022
Epilepsy - Pipeline by Medicure Inc, 2022
Epilepsy - Pipeline by Mediphage Bioceuticals Inc, 2022
Epilepsy - Pipeline by Medlab Clinical Ltd, 2022
Epilepsy - Pipeline by Mercaptor Discoveries Inc, 2022
Epilepsy - Pipeline by Metys Pharmaceuticals AG, 2022
Epilepsy - Pipeline by MGC Pharmaceuticals Ltd, 2022
Epilepsy - Pipeline by Mucodel Pharma LLC, 2022
Epilepsy - Pipeline by MyMD Pharmaceuticals, Inc, 2022
Epilepsy - Pipeline by MyX Therapeutics Inc, 2022
Epilepsy - Pipeline by Nasus Pharma Ltd, 2022
Epilepsy - Pipeline by Navega Therapeutics Inc, 2022
Epilepsy - Pipeline by Navitor Pharmaceuticals Inc, 2022
Epilepsy - Pipeline by Neonc Technologies Inc, 2022
Epilepsy - Pipeline by NeuCyte Inc, 2022
Epilepsy - Pipeline by NeuExcell Therapeutics Inc, 2022
Epilepsy - Pipeline by NeurAegis Inc, 2022
Epilepsy - Pipeline by Neuraxpharm France SAS, 2022
Epilepsy - Pipeline by Neurelis Inc, 2022
Epilepsy - Pipeline by NeuroAdjuvants Inc, 2022
Epilepsy - Pipeline by Neurocrine Biosciences Inc, 2022

Epilepsy - Pipeline by Neuroene Therapeutics LLC, 2022
Epilepsy - Pipeline by Neurona Therapeutics Inc, 2022
Epilepsy - Pipeline by New Amsterdam Sciences Inc, 2022
Epilepsy - Pipeline by Nissan Chemical Corp, 2022
Epilepsy - Pipeline by Noema Pharma AG, 2022
Epilepsy - Pipeline by NoNO Inc, 2022
Epilepsy - Pipeline by NuBioPharma LLC, 2022
Epilepsy - Pipeline by OB Pharmaceuticals, 2022
Epilepsy - Pipeline by OMass Therapeutics Limited, 2022
Epilepsy - Pipeline by Oncocross Co Ltd, 2022
Epilepsy - Pipeline by Otsuka Pharmaceutical Co Ltd, 2022
Epilepsy - Pipeline by Ovid Therapeutics Inc, 2022
Epilepsy - Pipeline by OWP Pharmaceuticals Inc, 2022
Epilepsy - Pipeline by Panaxia Pharmaceutical Industries Ltd, 2022
Epilepsy - Pipeline by Pfizer Inc, 2022
Epilepsy - Pipeline by PharmaTher Holdings Ltd, 2022
Epilepsy - Pipeline by Pharmatrophix Inc, 2022
Epilepsy - Pipeline by PIQUR Therapeutics AG, 2022
Epilepsy - Pipeline by Praxis Precision Medicines Inc, 2022
Epilepsy - Pipeline by Primetime Life Sciences LLC, 2022
Epilepsy - Pipeline by Promius Pharma LLC, 2022
Epilepsy - Pipeline by Proniras Corp, 2022
Epilepsy - Pipeline by Protheragen Inc, 2022
Epilepsy - Pipeline by Proveca Ltd, 2022
Epilepsy - Pipeline by PTC Therapeutics Inc, 2022
Epilepsy - Pipeline by Puretech Health Plc, 2022
Epilepsy - Pipeline by Q-State Biosciences Inc, 2022
Epilepsy - Pipeline by Reata Pharmaceuticals Inc, 2022
Epilepsy - Pipeline by reMYND NV, 2022
Epilepsy - Pipeline by RespireRx Pharmaceuticals Inc, 2022
Epilepsy - Pipeline by RogCon Inc, 2022
Epilepsy - Pipeline by Sage Therapeutics Inc, 2022
Epilepsy - Pipeline by Saniona AB, 2022
Epilepsy - Pipeline by Scientus Pharma Inc, 2022
Epilepsy - Pipeline by SciSparc Ltd, 2022
Epilepsy - Pipeline by Serina Therapeutics Inc, 2022
Epilepsy - Pipeline by Shackelford Pharma Inc, 2022
Epilepsy - Pipeline by Shanghai Lvdao Pharmaceutical Technology Co Ltd, 2022
Epilepsy - Pipeline by Shanghai Zhimeng Biopharma Inc, 2022

Epilepsy - Pipeline by Simcere Pharmaceutical Group Ltd, 2022
Epilepsy - Pipeline by SK Biopharmaceuticals Co Ltd, 2022
Epilepsy - Pipeline by SK Chemicals Co Ltd, 2022
Epilepsy - Pipeline by Skye Bioscience Inc, 2022
Epilepsy - Pipeline by SoVarGen Co Ltd, 2022
Epilepsy - Pipeline by Spark Therapeutics Inc, 2022
Epilepsy - Pipeline by Stoke Therapeutics Inc, 2022
Epilepsy - Pipeline by StrideBio Inc, 2022
Epilepsy - Pipeline by Sumitomo Dainippon Pharma Co Ltd, 2022
Epilepsy - Pipeline by Sun Pharma Advanced Research Company Ltd, 2022
Epilepsy - Pipeline by Supernus Pharmaceuticals Inc, 2022
Epilepsy - Pipeline by Sustained Nano Systems LLC, 2022
Epilepsy - Pipeline by Tahoe Pharmaceuticals Ltd, 2022
Epilepsy - Pipeline by Takeda Pharmaceutical Co Ltd, 2022
Epilepsy - Pipeline by Tavanta Therapeutics Inc, 2022
Epilepsy - Pipeline by Taysha Gene Therapies Inc, 2022
Epilepsy - Pipeline by Techfields Pharma Co Ltd, 2022
Epilepsy - Pipeline by Tevard Biosciences LLC, 2022
Epilepsy - Pipeline by The Cell Factory BVBA, 2022
Epilepsy - Pipeline by Trevena Inc, 2022
Epilepsy - Pipeline by UCB SA, 2022
Epilepsy - Pipeline by Ultragenyx Pharmaceutical Inc, 2022
Epilepsy - Pipeline by Viatrix Inc, 2022
Epilepsy - Pipeline by Virpax Pharmaceuticals Inc, 2022
Epilepsy - Pipeline by VistaGen Therapeutics Inc, 2022
Epilepsy - Pipeline by Vitality Biopharma Inc, 2022
Epilepsy - Pipeline by Vyripharm Biopharmaceuticals, 2022
Epilepsy - Pipeline by Whan In Pharm Co Ltd, 2022
Epilepsy - Pipeline by Xenon Pharmaceuticals Inc, 2022
Epilepsy - Pipeline by Xeris Biopharma Holdings Inc, 2022
Epilepsy - Pipeline by XPhyto Therapeutics Corp, 2022
Epilepsy - Pipeline by XWPharma Ltd, 2022
Epilepsy - Pipeline by Zhejiang Conba Pharmaceutical Co Ltd, 2022
Epilepsy - Pipeline by Zogenix Inc, 2022
Epilepsy - Pipeline by Zynerba Pharmaceuticals Inc, 2022
Epilepsy - Dormant Projects, 2022
Epilepsy - Discontinued Products, 2022
Epilepsy - Discontinued Products, 2022 (Contd..1)

List Of Figures

LIST OF FIGURES

Number of Products under Development for Epilepsy, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022

I would like to order

Product name: Epilepsy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/E3E6FB1485F6EN.html>

Price: US\$ 2,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/E3E6FB1485F6EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

